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Abstract 
Background: A genome-wide study identified de novo DNA methylation alterations in leukocytes of children at pae-
diatric intensive care unit (PICU) discharge, offering a biological basis for their impaired long-term development. Early 
parenteral nutrition (early-PN) in PICU, compared with omitting PN in the first week (late-PN), explained differential 
methylation of 23% of the affected CpG-sites. We documented the time course of altered DNA methylation in PICU 
and the impact hereon of early nutritional management.
Results: We selected 36 early-PN and 36 late-PN matched patients, and 42 matched healthy children. We quantified 
DNA methylation on days 3, 5 and 7 for the 147 CpG-sites of which methylation was normal upon PICU admission 
in this subset and altered by critical illness at PICU discharge. Methylation in patients differed from healthy children 
for 64.6% of the 147 CpG-sites on day 3, for 72.8% on day 5 and for 90.5% on day 7 as revealed by ANOVA at each 
time point. Within-patients methylation time course analyses for each CpG-site identified different patterns based on 
paired t test p value and direction of change. Rapid demethylation from admission to day 3 occurred for 76.2% of the 
CpG-sites, of which 67.9% remained equally demethylated or partially remethylated and 32.1% further demethylated 
beyond day 3. From admission to day 3, 19.7% of the CpG-sites became hypermethylated, of which, beyond day 3, 
34.5% remained equally hypermethylated or partially demethylated again and 65.5% further hypermethylated. For 
4.1% of the CpG-sites, changes only appeared beyond day 3. Finally, for the CpG-sites affected by early-PN on the last 
PICU day, earlier changes in DNA methylation were compared for early-PN and late-PN patients, revealing that 38.9% 
were already differentially methylated by day 3, another 25.0% by day 5 and another 13.9% by day 7.
Conclusions: Critical illness- and early-PN-induced changes in DNA methylation occurred mainly within 3 days. Most 
abnormalities were at least partially maintained or got worse with longer time in PICU. Interventions targeting aber-
rant DNA methylation changes should be initiated early.
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Background
Children who have been critically ill and required treat-
ment in the paediatric intensive care unit (PICU) often 
suffer from adverse long-term health and developmental 
sequelae that are present years after hospital discharge 
[1]. Impaired neurocognitive development has been 
most thoroughly documented, but also growth retarda-
tion, poor physical functioning and long-term health 
risks have been reported [1–4]. Part of this long-term 
legacy appears preventable through altering aspects of 
the intensive care management. For example, nutritional 
management during critical illness was found to modify 
not only short-term outcome of critically ill children, 
but also the long-term legacy [5–9]. Indeed, providing 
full nutritional intake early with the use of parenteral 
nutrition (PN) to supplement insufficient enteral nutri-
tion (early-PN) has shown to be clinically inferior than 
accepting the early macronutrient deficit by postponing 
any PN to beyond the first week in PICU (late-PN). Early-
PN not only caused more infections and delayed recovery 
from the illness, it also prevented normal development of 
executive functions and/or caused behavioural problems, 
as assessed 2 and 4 years later [5, 8, 9].
We have recently provided evidence for a molecular 
basis of the long-term developmental legacy of criti-
cal illness and of the role of early-PN herein. In a large 
genome-wide study, we have shown that critical illness 
and the administration of early-PN during critical illness 
altered methylation of DNA extracted from peripheral 
blood of these young patients [10]. More specifically, at 
the day of PICU discharge, we documented alterations in 
methylation of several CpG-sites, changes that were not 
yet present upon PICU admission. Several of the affected 
CpG-sites were located in genes involved in a variety of 
relevant molecular functions, physical and neurocogni-
tive developmental processes and in neurodegenerative 
and psychiatric diseases. The use of early-PN explained 
23% of these de novo changes in DNA methylation. 
Importantly, these changes in DNA methylation statisti-
cally explained an important part of the negative impact 
of critical illness and of early-PN on neurocognitive 
development 2 years later.
The previous work thus revealed that DNA methylation 
is altered by critical illness and/or its intensive care man-
agement. However, it remained unclear how fast these 
changes in DNA methylation occur and how they evolve 
over time in the PICU. In a subset of matched patients 
and controls, we therefore documented the time course 
in PICU of the DNA methylation status of the CpG-sites 
of which methylation status was normal upon PICU 
admission, but previously shown to become aberrant at 
the day of PICU discharge [10], and studied the impact 
hereon of the use of early-PN versus late-PN.
Results
Participant characteristics
Demographics of the 42 healthy children and demo-
graphics and medical characteristics of the 72 patients 
upon PICU admission selected for this study are shown 
in Table 1. Total energy intake of patients was higher in 
the early-PN group than in the late-PN group on each of 
the first 7 days in PICU (Additional file 3).
Studied CpG‑sites
We performed this study on the 147 CpG-sites of which 
methylation status was previously shown to be altered by 
critical illness and/or its intensive care management [10] 
but normal upon PICU admission in the current partici-
pants’ subset. For 36 of these 147 CpG-sites, the use of 
early-PN versus late-PN contributed to the differential 
methylation [10].
The studied CpG-sites are clinically relevant, since 
DNA  methylation alterations that occur in these CpG-
sites during PICU stay were shown to play a mediating 
role in the negative impact of critical illness and, for 36 
of them of early-PN versus late-PN during critical ill-
ness, on the long-term neurocognitive development of 
children [10]. Location of the 147 studied CpG-sites and 
gene-related protein functions are shown in Additional 
file 4.
DNA methylation alterations over time in 147 CpG‑sites 
in critically ill patients versus healthy children
At PICU day 3, 64.6% of the CpG-sites already showed a 
significant difference in methylation status in patients as 
compared with healthy children (Additional file 5). This 
fraction increased to 72.8% by day 5 and to 90.5% by day 
7.
Pattern analysis of DNA methylation alterations over time 
in 147 CpG‑sites affected by critical illness
The time series of the within-patient changes in DNA 
methylation revealed three major pattern categories 
between PICU admission and day 3, which could be 
further divided into six patterns based on the evolution 
beyond day 3. The detailed time courses of representative 
Keywords: Paediatric intensive care unit, PICU, Critical illness, Nutrition, Parenteral nutrition, DNA methylation, 
Epigenetics, Time, Time course
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Table 1 Demographics of participants and medical characteristics of patients upon PICU admission
PN parenteral nutrition, SEM standard error of the mean, PICU paediatric intensive care unit, STRONGkids screening tool for risk on nutritional status and growth, 
PeLOD paediatric logistic organ dysfunction, PIM3 paediatric index of mortality 3
a The educational and occupational level is the mean of the paternal and maternal educational or occupational level (Additional file 1)
b STRONGkids scores range from 0 to 5, with a score of 0 indicating a low risk of malnutrition, a score of 1–3 indicating a medium risk, and a score of 4–5 indicating a 
high risk
c PeLOD scores range from 0 to 71, with higher scores indicating more severe illness
PICU patients Healthy controls p value PICU patients
Early‑PN
PICU patients
Late‑PN
p value
n = 42 n = 42 n = 36 n = 36
Demographics
Age (mean ± SEM)—years 3.9 ± 0.6 3.8 ± 0.5 0.93 2.6 ± 0.7 2.1 ± 0.5 0.57
Infant (age < 1 year)—no. (%) 14 (33) 10 (24) 0.33 22 (61) 22 (61) 1.00
Sex 0.82 0.81
 Female—no. (%) 21 (50) 22 (48) 15 (42) 14 (39)
 Male—no. (%) 21 (50) 20 (52) 21 (58) 22 (61)
Socio-economic  statusa
Educational level of the parents – 0.13
 Parents educational level 1.5—no. (%) 3 (7) NA 4 (11) 1 (3)
 Parents educational level 2—no. (%) 10 (24) NA 11 (31) 9 (25)
 Parents educational level 2.5—no. (%) 6 (14) NA 4 (11) 7 (19)
 Parents educational level 3—no. (%) 10 (24) NA 6 (17) 13 (36)
 Parents educational level unknown—no. (%) 13 (31) NA 11 (31) 6 (17)
Occupational level of the parents – 0.28
 Parents occupational level 1.5—no. (%) 2 (5) NA 2 (6) 2 (6)
 Parents occupational level 2—no. (%) 8 (19) NA 8 (22) 8 (22)
 Parents occupational level 2.5—no. (%) 2 (5) NA 2 (6) 3 (8)
 Parents occupational level 3—no. (%) 7 (17) NA 5 (14) 9 25)
 Parents occupational level 3.5—no. (%) 1 (2) NA 1 (3) 0 (0)
 Parents occupational level 4—no. (%) 5 (12) NA 3 (8) 7 (19)
 Parents occupational level unknown—no. (%) 17 (40) NA 15 (41) 7 (19)
Patient characteristics upon PICU admission
Weight z-score (mean ± SEM) − 0.45 ± 0.23 NA – − 0.48 ± 0.21 − 0.41 ± 0.25 0.84
Height z-score (mean ± SEM) − 0.63 ± 0.34 NA – − 0.61 ± 0.28 − 0.21 ± 0.36 0.39
STRONGkids risk  levelb – 0.15
 Medium—no. (%) 38 (90) NA 35 (97) 32 (89)
 High—no. (%) 4 (10) NA 1 (3) 4 (11)
PeLOD score first 24 h in PICU (mean ± SEM)c 28.3 ± 1.4 NA – 29.4 ± 1.5 30.0 ± 1.2 0.72
PIM3 score (mean ± SEM)d − 3.06 ± 0.17 NA – − 2.87 ± 0.20 − 3.23 ± 0.12 0.13
Infection upon PICU admission 14 (33) NA – 9 (25) 9 (25) 1.00
Diagnostic  categorye NA – 0.23
 Surgical-cardiac—no. (%) 23 (55) NA 24 (67) 27 (75)
 Surgical-other—no. (%) 4 (10) NA 3 (8) 2 (6)
 Neurosurgery/neurology—no. (%) 6 (14) NA 4 (11) 2 (6)
 Trauma/burn—no. (%) 1 (2) NA 0 (0) 1 (3)
 Transplantation/haematology/oncology—no. (%) 2 (5) NA 1 (3) 1 (3)
 Medical-other—no. (%) 6 (14) NA 4 (11) 3 (8)
History of malignancy—no. (%) 5 (12) NA – 3 (8) 2 (6) 0.64
Diabetes—no. (%) 0 (0) NA – 0 (0) 0 (0) –
Predefined syndrome—no. (%)f 8 (19) NA – 8 (22) 3 (8) 0.09
Randomisation
Early-PN—no. (%) 19 (45) NA – 36 (100) 0 (0) –
Late-PN—no. (%) 23 (55) NA – 0 (0) 36 (100) –
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CpG-sites for each of these patterns are illustrated in 
Fig. 1 and Additional file 6. Additionally, heatmaps were 
constructed providing an overview of all CpG-sites of the 
four most abundant patterns (Additional file 7).
In the first pattern category, which covered the major-
ity (76.2%) of the CpG-sites, rapid demethylation 
occurred between admission and day 3 (paired t test 
p < 0.05). Beyond day 3, 67.9% of these CpG-sites subse-
quently remained equally demethylated or only partially 
remethylated (pattern 1), whereas the other 32.1% further 
demethylated beyond day 3 (pattern 2), although mostly 
at a slower rate.
In the second pattern category, hypermethylation of 
19.7% of the CpG-sites occurred between admission and 
day 3 (paired t test p < 0.05). Beyond day 3, 34.5% of these 
CpG-sites remained equally hypermethylated or only 
partially demethylated again (pattern 3), while the other 
65.5% further hypermethylated beyond day 3 (pattern 
4). The further hypermethylation mostly progressed at a 
slower rate than the initial rise towards day 3.
The third pattern category covered 4.1% of CpG-sites 
of which methylation did not change between admis-
sion and day 3 (paired t test p > 0.05) and for which clear 
changes became visible only beyond day 3. Of these CpG-
sites, 50% showed a delayed demethylation (pattern 5) 
and 50% showed a delayed hypermethylation (pattern 6).
Pattern analysis of DNA methylation alterations over time 
in 36 CpG‑sites affected by early‑PN versus late‑PN 
during critical illness
Of the CpG-sites of which DNA methylation was previ-
ously shown to be affected by early-PN versus late-PN 
on the last PICU day [10], 33.3% were assigned to pat-
tern 1 (rapid demethylation followed by equally main-
tained demethylation or only partial remethylation), 
38.9% to pattern 2 (rapid demethylation followed by 
further demethylation), 5.6% to pattern 3 (rapid hyper-
methylation followed by equally maintained hypermeth-
ylation or only partial demethylation), and 22.2% to 
pattern 4 (rapid hypermethylation followed by even fur-
ther hypermethylation).
The DNA  methylation time course for representa-
tive CpG-sites of pattern 1 to 4 in early-PN versus late-
PN patients is shown in Fig. 2. In late-PN patients, DNA 
methylation generally remained relatively stable with less 
obvious changes, whereas time-dependent patterns were 
observed in the early-PN patients. Of these CpG-sites 
affected by early-PN versus late-PN by PICU discharge, 
38.9% became differentially methylated between early-
PN and late-PN patients already on day 3, another 25.0% 
of these CpG-sites became differentially methylated by 
day 5 and another 13.9% by day 7.
Discussion
This study aimed at visualising time courses and patterns 
of the previously identified abnormal DNA methylation 
brought about by critical illness, in part attributable to 
early use of PN. The study revealed that most abnor-
mal DNA methylation occurred fast, most often within 
3 days, and that most abnormalities were at least partially 
maintained or got worse over the first week in the PICU.
It is known that the epigenome has a great plastic-
ity and undergoes physiological and disease-associated 
alterations in response to internal and external stimuli 
[11, 12]. Although studies on DNA methylation dynam-
ics evaluating intraindividual longitudinal changes in 
DNA methylation are scarce, there is emerging evidence 
that an individual’s DNA methylation profile is subject to 
change on both a short- (hours to days) and long-term 
(months to years) timescale [13, 14]. For the majority of 
d Higher PIM3 scores indicate a higher risk of mortality
e ‘Surgical-other’ includes abdominal, thoracic or, other surgery. ‘Medical-other’ includes cardiac, gastrointestinal or hepatic, renal, respiratory or, other medical 
problems
f A predefined syndrome is any pre-randomisation syndrome or illness a priori defined as affecting or possibly affecting neurocognitive development (Additional 
file 2)
Table 1 (continued)
Fig. 1 Evolution of DNA methylation over time in critically patients. Detailed time profiles are shown for 14 representative CpG-sites distributed 
over the identified patterns of changes in methylation status in PICU. Separate graphs are shown for patients in PICU for at least 3 days, at 
least 5 days, or at least 7 days. Data are presented as mean and standard error. n represents the number of patients with samples available at 
the respective time points. p values shown were obtained with paired t tests and represent the comparison with the previous time point. *p 
value ≤ 0.05, **p value ≤ 0.01, ***p value ≤ 0.001. Tests were not performed to compare the last PICU day with the previous time point, in view of 
the variability of the last day (which also was equal to day 3, day 5 or day 7 for some of the patients). Δd0: β value day 0 minus β value day 0, Δd3: β 
value day 3 minus β value day 0, Δd5: β value day 5 minus β value day 0, ∆d7: β value day 7 minus β value day 0, ΔLd: β value last PICU day minus β 
value day 0
(See figure on next page.)
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the CpG-sites investigated in the present study, the larg-
est changes in DNA methylation status occurred within 
the first 3  days after PICU admission, whereas any fur-
ther changes beyond day 3 progressed at a slower rate. 
Earlier research in other fields also documented short-
term DNA methylation alterations in several CpG-sites, 
for instance within only hours after metformin admin-
istration [15], or within a few days after the start of a 
detoxification treatment in alcohol-dependent individu-
als [16]. Also, in physiologic conditions, DNA demethyla-
tion and methylation can occur rapidly, such as within a 
timeframe of several hours after fertilisation [17].
This study started from the previously identified de 
novo alterations in DNA methylation that arose after 
PICU admission and remained present until discharge 
from the PICU [10]. We distinguished different patterns 
among the time-dependent changes in methylation sta-
tus of the studied CpG-sites during PICU stay. For sev-
eral of the studied CpG-sites that underwent an initial 
rapid demethylation or hypermethylation, changes were 
at least partially maintained beyond day 3 in the PICU, 
whereas others continued along the line of further dem-
ethylation or hypermethylation. How long the identified 
DNA  methylation alterations persist in children who 
have been critically ill remains to be investigated. Partial 
reversibility of DNA methylation would be consistent 
with previous findings on the evolution of tobacco smok-
ing-related epigenetic changes after smoking cessation. 
Indeed, in former smokers, two classes of CpG-sites were 
described with, on the one hand, CpG-sites of which 
the methylation status reverted to levels of typical never 
smokers after smoking cessation and, on the other hand, 
CpG-sites that remained differentially methylated even 
up to more than 35 years after smoking cessation [18].
Multiple factors may contribute to the rapid changes in 
DNA methylation in critically ill children. Critical illness 
represents a severe physical stress, which rapidly acti-
vates a variety of neuronal, humoral and inflammatory 
Fig. 2 Evolution of DNA methylation over time in early-PN versus late-PN patients. Detailed time profiles are shown for four representative 
CpG-sites distributed over the four major identified patterns of changes in methylation status in PICU. Black lines represent the patients in the 
early-PN group, and grey lines represent patients in the late-PN group (pooled profiles for early-PN and late-PN patients are shown in Fig. 1). 
Separate graphs are shown for patients in PICU for at least 3 days, at least 5 days, or at least 7 days. Data are presented as mean and standard error. 
n represents the number of patients with samples available at the respective time points. p values shown were obtained with t tests and represent 
the comparison among patients in the early-PN and late-PN groups at day 3, day 5 or day 7. *p value ≤ 0.05, **p value ≤ 0.01, ***p value ≤ 0.001. 
Tests were not performed to compare early-PN and late-PN on the last PICU day, in view of the variability of the last day (which also was equal to 
day 3, day 5 or day 7 for some of the patients). Δd0: β value day 0 minus β value day 0, Δd3: β value day 3 minus β value day 0, Δd5: β value day 5 
minus β value day 0, ∆d7: β value day 7 minus β value day 0, ΔLd: β value last PICU day minus β value day 0
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pathways [19]. Activation of these pathways has been 
linked with several DNA  methylation alterations and 
could thus play a role [20–22]. Also, nutrition can affect 
epigenetic mechanisms, directly via products of inter-
mediary metabolism [23] or indirectly via the ability 
to activate several inflammatory pathways [24–26]. As 
described, early-PN as compared with late-PN inde-
pendently contributed to the alterations in 23% of the 
CpG-sites that became differentially methylated by the 
last PICU day as compared with healthy children [10]. 
We have now shown that when comparing patients 
in the early-PN and late-PN group, the dynamic pro-
files of the changes in most of these CpG-sites already 
separated early within the first 3 to 5  days after PICU 
admission. DNA methylation in the late-PN patients 
in general remained relatively stable with less obvious 
changes, whereas the time-dependent patterns were 
mostly observed in the early-PN patients, suggesting 
that changes documented for the total group of critically 
ill children are mainly caused by the use of early-PN in 
these CpG-sites. The present data, showing that the aber-
rant DNA methylation changes that have previously been 
associated with impaired long-term developmental out-
come of critically ill children [10] arise already very early 
after PICU admission, indicate that interventions aimed 
at the attenuation of such changes should be initiated 
from early onwards in the disease process. Withhold-
ing early-PN indeed partially prevented early aberrant 
changes in DNA methylation and partially protected 
against developmental impairments. This opens per-
spectives for other interventions that target the residual 
changes to further improve long-term developmental 
outcome of critically ill children.
Strengths of this study include the paired measure-
ments per patient that allowed evaluation of within-
patient evolution of DNA  methylation status over time, 
the randomised controlled study design of the PEPaNIC 
trial, and the further building of this study on the previ-
ous rigorous, very stringent identification of CpG-sites 
affected by critical illness and early nutritional manage-
ment in a large genome-wide DNA  methylation study 
[10]. This study also has some weaknesses. First, the sam-
ple size of patients who were included in this time course 
study was substantially smaller as compared with the 
original study cohort, reducing statistical power. How-
ever, in this well-matched subset, within-patient changes 
could be analysed. Second, the classification of these 
within-patient DNA  methylation time series into pat-
terns was to a certain degree arbitrary. Third, except for 
the initial comparison of critically ill with healthy chil-
dren, we did not correct for multiple testing. This was 
considered appropriate given that the aim of the second 
part of this study was to recognise patterns rather than 
absolute differences. Finally, we did not pursue mecha-
nistic analyses beyond identifying the time course of 
DNA methylation changes.
Conclusions
DNA  methylation changes evoked by critical illness in 
children and by the administration of early-PN in PICU 
occurred rapidly, mostly within the first few days of PICU 
admission. With longer time spent in the PICU after 
these first days, most abnormalities in DNA methylation 
were at least partially maintained or got worse. Future 
interventions aimed at attenuating such aberrant changes 
in DNA methylation should be initiated early after PICU 
admission.
Methods
Study population and blood sampling
This study is a preplanned secondary analysis of the 
multicentre PEPaNIC randomised controlled trial that 
included 1440 critically ill children aged 0–17  years 
admitted to the paediatric intensive care units of Leuven 
(Belgium), Rotterdam (The Netherlands) or Edmonton 
(Canada). Patients had been randomly assigned to early 
initiation of PN within 24 h when enteral nutrition was 
insufficient (early-PN), or to postponing any supplemen-
tal PN to beyond the first week in PICU (late-PN). After 
1  week, for both groups equally, PN could be adminis-
tered if necessary. The full study protocol and primary 
outcomes have been published [7]. Repeated blood cell 
samples, destined to the extraction of DNA, had been 
collected upon PICU admission, at day 3, day 5, and 
day 7, and at the last day in the PICU. For comparison 
with healthy control children, blood had been sampled 
from children who had never been admitted to a PICU 
(n = 352), immediately after placement of an intravenous 
catheter prior to minor elective surgery (Fig. 3) [10].
In order to document the time course of the de novo 
changes evoked by early-PN versus late-PN during PICU 
stay, in a financially feasible way and while avoiding con-
founders, a limited selection of well-matched patients 
was required (Table  1). To this end, we selected a sub-
group of 36 late-PN and 36 early-PN patients matched for 
baseline risk factors from all Leuven patients who needed 
intensive care for more than 3 days, who were discharged 
alive from PICU and for whom DNA was available for the 
admission day, day 3 and last day in PICU (Fig. 3). This 
matching was performed with the use of propensity score 
matching [SPSS R-menu R3.1 (Foundation for Statisti-
cal Computing) in IBM SPSS Statistics 23.0.0.0 (SPSS, 
Chicago, IL)]. Logistic regression was used to estimate 
propensity scores with the baseline risk factors age, type 
(admission diagnosis) and severity of illness (PeLOD 
score), infection upon admission, gender, height, weight 
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and educational level of the parents (Additional file  1) 
as covariates, and the caliper was set at 0.4. Of these 72 
patients, 55 also had a day 5 sample (27 early-PN, 28 late-
PN) and 30 had a day 7 sample (18 early-PN, 12 late-PN).
From these 72 patients, 42 (19 early-PN and 23 late-
PN) could subsequently be propensity score-matched 
with 42 healthy control children with age and gender as 
covariates and caliper 0.2 (Fig. 3). Of these 42 patients, 34 
had a day 5 sample (14 early-PN, 20 late-PN) and 18 had 
a day 7 sample (nine early-PN, nine late-PN).
DNA methylation assessment
Genomic DNA was extracted from the blood cell samples 
and bisulphite-converted. DNA extractions were per-
formed with the Maxwell®RSC instrument and the corre-
sponding blood DNA purification kit (Promega Benelux 
b.v., Leiden, The Netherlands). All DNA concentrations 
were accurately quantified with the Qubit® 3.0 fluorom-
eter (Thermo Fisher Scientific, Waltham, MA). Bisulphite 
conversion of the DNA (400  ng) was performed with 
the EZ DNA  Methylation-Direct® Kit (Zymo Research, 
Irvine, CA). For one PICU-day 3 sample, DNA yield was 
insufficient for further analysis.
A genome-wide DNA  methylation analysis of all 
samples was performed with the Infinium® Human-
Methylation EPIC BeadChip (Illumina Inc., San Diego, 
CA), interrogating > 850.000 CpG-sites per sample and 
spanning > 99% of genes in the Reference Sequence (Ref-
Seq) database [27].
Methylation data were preprocessed using Partek 
Genomics Suite® 7.0 (Partek, St. Louis, MO). Methyla-
tion β values ranging from 0 (no methylation) to 1 (full 
methylation) were obtained after background and func-
tional normalisation of the raw intensities (i.e. an exten-
sion to quantile normalisation that removes unwanted 
technical variation using control probes). The data were 
subsequently subjected to several quality assessments at 
sample and probe level. First, sample histogram forma-
tion assessed the bipeak curve of the β value distribution 
among the samples in the low- and high-end range, and 
principal component analysis (PCA) assessed the vari-
ance in the dataset [10]. Next, of the 159 CpG-sites that 
we had previously identified in a genome-wide DNA 
methylation study as affected by critical illness in children 
[10], β values on the different time points were selected 
for further analyses. These 159 CpG-sites became differ-
entially methylated in leukocytes of critically ill children 
by PICU discharge (n = 814) as compared with healthy 
matched peers, but were not yet differentially methylated 
upon PICU admission. CpG-sites that were already dif-
ferentially methylated upon PICU admission had been 
excluded preceding this analysis to avoid detection of 
changes explained by premorbid conditions or illness-
induced alterations in leukocyte composition. Early-PN, 
1440 PICU patients in PEPaNIC-RCT
750 patients treated in Leuven PICU
355 PICU survivors with admission,
day 3 and last day white blood cell
sample
352 healthy children
72 PICU survivors with admission,
day 3 and last day white blood cell
sample
42 PICU survivors with admission,
day 3 and last day white blood cell
sample
42 healthy children
36 early-PN
36 late-PN
Fig. 3 CONSORT diagram of study participants. PICU: paediatric intensive care unit, PEPaNIC: Paediatric Early versus Late Parenteral Nutrition in 
Intensive Care Unit, RCT: randomised controlled trial, PN: parenteral nutrition
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independent of its slowing effect on recovery, contrib-
uted to differential methylation of 37 of the 159 CpG-
sites [10].
For the current time course study, of the 159 previously 
identified CpG-sites of which methylation was shown to 
be altered by critical illness and the 37 previously shown 
to be affected by the use of early-PN versus late-PN, only 
those with normal methylation upon PICU admission in 
the current subset were selected for further analysis [10].
Statistical analyses
In a first part of this study, we focused on a statistical 
approach to identify differences in DNA methylation 
over time in PICU patients versus healthy children with 
the use of ANOVA and application of a false discovery 
rate (FDR) of 0.05 to account for multiple testing. CpG-
sites already differentially methylated at PICU admis-
sion in the subset selected for the present study were first 
identified, revealing 12 CpG-sites to be discarded for fur-
ther time profile analyses (Additional file 8). Following a 
similar approach, we then investigated whether the 147 
remaining CpG-sites were already differentially meth-
ylated at three earlier time points (PICU day 3, 5 and 7) 
preceding PICU discharge.
Next, we applied a descriptive approach to study the 
altered methylation of each of these CpG-sites separately 
via a within-patient time course pattern recognition 
analysis. To this end, we plotted the DNA  methylation 
changes (∆ DNA methylation) from admission to the 
respective time points (day 3, day 5, day 7 and last day in 
PICU) and searched for patterns among these time series. 
We first identified pattern categories based on the early 
response, i.e. change in DNA methylation status between 
admission and day 3, taking into account the p value of 
paired t tests and direction of change. Given the specific 
descriptive aim of pattern recognition, no correction was 
done for multiple comparisons. These pattern categories 
were subsequently further categorised for the visualised 
time course beyond day 3. To reduce bias induced by 
length of stay, we performed sensitivity analyses for the 
patients who stayed in PICU for at least 3 days, at least 
5 days or at least 7 days, respectively.
Finally, we followed a similar approach to study the 
impact of early-PN versus late-PN on the time course of 
the CpG-sites affected by this intervention. Changes in 
DNA methylation status in early-PN and late-PN patients 
were compared with Student t test. Again, given the spe-
cific aim of comparing patterns, no correction for multi-
ple comparisons was done.
Analyses were performed with the use of Partek 
Genomics Suite® (Partek, St. Louis, MO), R version 3.5.3 
and JMP© version 14.0.0 (SAS Institute, Inc, Cary, NC). 
p values ≤ 0.05 or FDR cut-off of 0.05 was considered to 
indicate statistical significance.
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Supplementary information accompanies this paper at https ://doi.
org/10.1186/s1314 8-020-00947 -w.
Additional file 1. Definition of educational and occupational level of 
parents
Additional file 2. Definition of ‘syndrome’.
Additional file 3. Total energy intake of early-PN and late-PN patients on 
the first 7 days in PICU. Bar graphs showing total energy intake of early-PN 
and late-PN patients on the first 7 days in PICU.
Additional file 4. Location and gene-related protein functions of 147 
studied CpG-sites. Location of the 147 studied CpG-sites within gene sec-
tion or intergenic region and corresponding protein function if applicable, 
ordered according to the different patterns identified.
Additional file 5. Summary of ANOVA results comparing DNA methyla-
tion levels in patients at different time points during PICU stay versus 
healthy children. DNA methylation levels of the 147 CpG-sites that were 
not yet differentially methylated in patients upon PICU admission versus 
healthy children were compared for patients at day 3, day 5 and day 7 in 
PICU versus healthy children with the use of ANOVA and application of a 
false discovery rate of 0.05, with reporting of unadjusted p values.
Additional file 6. Evolution of DNA methylation over time of pattern 1–4 
in individual critically ill patients. Detailed time profiles are shown for ten 
patients of representative CpG-sites classified to pattern 1, pattern 2, pat-
tern 3, and pattern 4.
Additional file 7. Heatmaps of changes in methylation status of all 
studied CpG-sites of patterns 1–4. Heatmaps summarising the changes 
in methylation status of the CpG-sites classified to pattern 1, pattern 2, 
pattern 3 and pattern 4.
Additional file 8. Identification of CpG-sites differentially methylated 
in patients upon PICU admission as compared with healthy children. 
DNA methylation levels of patients upon PICU admission were compared 
with those of healthy children with the use of ANOVA and application 
of a false discovery rate of 0.05. Unadjusted p values for the 12 CpG-sites 
already differentially methylated in patients upon PICU admission versus 
healthy controls are shown.
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